Literature DB >> 21189450

Chimeric p53 as an alternative therapy for hypoxic tumors.

Jun-Ho Lee1, Hua Lu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21189450      PMCID： PMC3047102          DOI： 10.4161/cbt.11.1.14526

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  31 in total

1.  In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA.

Authors:  S R Schwarze; S F Dowdy
Journal:  Trends Pharmacol Sci       Date:  2000-02       Impact factor: 14.819

2.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration.

Authors:  H Nagahara; A M Vocero-Akbani; E L Snyder; A Ho; D G Latham; N A Lissy; M Becker-Hapak; S A Ezhevsky; S F Dowdy
Journal:  Nat Med       Date:  1998-12       Impact factor: 53.440

3.  Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein.

Authors:  M Green; P M Loewenstein
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

4.  Tat protein from human immunodeficiency virus forms a metal-linked dimer.

Authors:  A D Frankel; D S Bredt; C O Pabo
Journal:  Science       Date:  1988-04-01       Impact factor: 47.728

5.  The third helix of the Antennapedia homeodomain translocates through biological membranes.

Authors:  D Derossi; A H Joliot; G Chassaing; A Prochiantz
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

6.  Hypoxia-regulated expression of attenuated diphtheria toxin A fused with hypoxia-inducible factor-1alpha oxygen-dependent degradation domain preferentially induces apoptosis of hypoxic cells in solid tumor.

Authors:  Nobuko Koshikawa; Keizo Takenaga
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

7.  Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.

Authors:  Hiroshi Harada; Masahiro Hiraoka; Shinae Kizaka-Kondoh
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

8.  A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth.

Authors:  Zhao Yu; Junhua Wu; Shaoping Wu; Peiyuan Jia; Ying Tong; Xumin Wu; Yuxia Wang
Journal:  Cancer Lett       Date:  2009-02-15       Impact factor: 8.679

9.  Intracellular delivery of p53 fused to the basic domain of HIV-1 Tat.

Authors:  Jiyoon Ryu; Hak Joo Lee; Kyeong-Ae Kim; Jae Yong Lee; Kil Soo Lee; Jinseu Park; Soo Young Choi
Journal:  Mol Cells       Date:  2004-04-30       Impact factor: 5.034

10.  Functional mechanisms for human tumor suppressors.

Authors:  Wanpeng Sun; Jian Yang
Journal:  J Cancer       Date:  2010-09-15       Impact factor: 4.207
View more
  2 in total

1.  MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis.

Authors:  Chang Hui; Fu Yujie; Yuan Lijia; Yi Long; Xu Hongxia; Zhou Yong; Zhu Jundong; Zhang Qianyong; Mi Mantian
Journal:  Breast Cancer Res       Date:  2012-05-22       Impact factor: 6.466

2.  Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain.

Authors:  Gobinda Sarkar; Geoffry L Curran; Jann N Sarkaria; Val J Lowe; Robert B Jenkins
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.